DK3597663T3 - Kimære antigenreceptorer af anti-cd70 - Google Patents
Kimære antigenreceptorer af anti-cd70 Download PDFInfo
- Publication number
- DK3597663T3 DK3597663T3 DK19178931.2T DK19178931T DK3597663T3 DK 3597663 T3 DK3597663 T3 DK 3597663T3 DK 19178931 T DK19178931 T DK 19178931T DK 3597663 T3 DK3597663 T3 DK 3597663T3
- Authority
- DK
- Denmark
- Prior art keywords
- chimary
- antigen receptors
- receptors
- antigen
- chimary antigen
- Prior art date
Links
- 102000006306 Antigen Receptors Human genes 0.000 title 1
- 108010083359 Antigen Receptors Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464436—Cytokines
- A61K39/464438—Tumor necrosis factors [TNF], CD70
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462088882P | 2014-12-08 | 2014-12-08 | |
EP15718065.4A EP3230310B1 (en) | 2014-12-08 | 2015-04-09 | Anti-cd70 chimeric antigen receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3597663T3 true DK3597663T3 (da) | 2022-06-27 |
Family
ID=52997584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK19178931.2T DK3597663T3 (da) | 2014-12-08 | 2015-04-09 | Kimære antigenreceptorer af anti-cd70 |
Country Status (12)
Country | Link |
---|---|
US (3) | US10689456B2 (da) |
EP (3) | EP3230310B1 (da) |
JP (3) | JP6724009B2 (da) |
CN (2) | CN107207616B (da) |
AU (3) | AU2015361261B2 (da) |
CA (1) | CA2970280A1 (da) |
DK (1) | DK3597663T3 (da) |
ES (2) | ES2921208T3 (da) |
PL (1) | PL3230310T3 (da) |
PT (1) | PT3230310T (da) |
SI (1) | SI3230310T1 (da) |
WO (1) | WO2016093878A1 (da) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10689456B2 (en) * | 2014-12-08 | 2020-06-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD70 chimeric antigen receptors |
CN105949325B (zh) * | 2016-07-08 | 2019-07-16 | 重庆精准生物技术有限公司 | 包含cd27胞内结构域的嵌合抗原受体、慢病毒载体及其应用 |
WO2018027197A1 (en) | 2016-08-04 | 2018-02-08 | Memorial Sloan-Kettering Cancer Center | Cancer antigen targets and uses thereof |
US11788093B2 (en) | 2017-09-07 | 2023-10-17 | University Of Florida Research Foundation, Inc. | Chimeric antigen receptor t-cells expressing interleukin-8 receptor |
GB201720949D0 (en) * | 2017-12-15 | 2018-01-31 | Autolus Ltd | Cell |
CN112020518A (zh) * | 2018-02-01 | 2020-12-01 | 辉瑞公司 | 靶向cd70的嵌合抗原受体 |
CA3099364A1 (en) * | 2018-05-11 | 2019-11-14 | Crispr Therapeutics Ag | Methods and compositions for treating cancer comprising engineered t cells comprising modified chimeric antigen receptors |
CN112533953A (zh) * | 2018-08-02 | 2021-03-19 | 凯德药业股份有限公司 | 嵌合抗原受体疗法t细胞扩增动力学及其用途 |
CN109880802B (zh) * | 2018-11-30 | 2022-12-13 | 北京美康基免生物科技有限公司 | 一种基于cd19和cd70的双重嵌合抗原受体基因修饰的免疫细胞及其应用 |
US20200384278A1 (en) * | 2019-06-04 | 2020-12-10 | Jerome Canady Research Institute for Advanced Biological and Technological Sciences | Method for Combination Cold Atmospheric Plasma and CAR-T Therapy |
EP4031150A4 (en) * | 2019-09-16 | 2023-11-01 | The General Hospital Corporation | CD70-DIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS AND USES THEREOF |
AU2021205249A1 (en) * | 2020-01-08 | 2022-07-21 | Board Of Regents, The University Of Texas System | A method of engineering natural killer cells to target CD70-positive tumors |
CN111909966B (zh) * | 2020-04-01 | 2021-09-21 | 苏州克睿基因生物科技有限公司 | 一种制备经修饰的免疫细胞的方法 |
EP4243839A1 (en) | 2020-11-13 | 2023-09-20 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
WO2022116952A1 (zh) * | 2020-12-01 | 2022-06-09 | 苏州克睿基因生物科技有限公司 | 靶向cd70的抗原结合蛋白及其应用 |
JP2023552895A (ja) | 2020-12-15 | 2023-12-19 | ユニフェルシテイト アントウェルペン | Cd70をターゲティングする細胞ベースの治療剤 |
WO2022159791A1 (en) * | 2021-01-25 | 2022-07-28 | Board Of Regents, The University Of Texas System | Cd27-extracellular domain car to target cd70-positive tumors |
TW202309077A (zh) * | 2021-05-12 | 2023-03-01 | 瑞士商Crispr治療公司 | 用於治療實性瘤的靶向cd70的基因工程化免疫細胞 |
WO2023072307A1 (zh) * | 2021-10-25 | 2023-05-04 | 重庆精准生物技术有限公司 | 一种靶向cd70的抗原结合片段、单链抗体和嵌合抗原受体及其应用 |
CN118126184A (zh) * | 2022-01-19 | 2024-06-04 | 上海恒润达生生物科技股份有限公司 | 抗cd70纳米抗体及其用途 |
WO2023196947A2 (en) * | 2022-04-07 | 2023-10-12 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of engineered natural killer cells and combinations with antibodies |
WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992001049A2 (en) * | 1990-07-13 | 1992-01-23 | The General Hospital Corporation | Cd53 cell surface antigen and use thereof |
US7285267B2 (en) * | 1997-01-14 | 2007-10-23 | Human Genome Sciences, Inc. | Tumor necrosis factor receptors 6α & 6β |
US20070037165A1 (en) | 2000-09-08 | 2007-02-15 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
US8034334B2 (en) | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
WO2008045437A2 (en) | 2006-10-09 | 2008-04-17 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
AU2010301042B2 (en) | 2009-10-01 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
EP2632482A4 (en) * | 2010-10-27 | 2015-05-27 | Baylor College Medicine | CHIMERIC CD27 RECEPTORS FOR REALIGNMENT OF T CELLS TO CD70 POSITIVE MALIGNOMES |
SG190997A1 (en) * | 2010-12-09 | 2013-07-31 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
JP6076963B2 (ja) * | 2011-04-08 | 2017-02-15 | アメリカ合衆国 | 抗上皮成長因子受容体変異体iiiキメラ抗原受容体及び癌の治療のためのその使用 |
JP6267644B2 (ja) | 2011-10-20 | 2018-01-24 | アメリカ合衆国 | 抗cd22キメラ抗原受容体 |
MX2014010183A (es) * | 2012-02-22 | 2015-03-20 | Univ Pennsylvania | Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer. |
CN103483452B (zh) | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
WO2014055771A1 (en) * | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
AU2013337926B2 (en) * | 2012-10-30 | 2017-12-21 | Esperance Pharmaceuticals, Inc. | Antibody/drug conjugates and methods of use |
CN104177499B (zh) * | 2013-05-27 | 2019-01-08 | 上海雅科生物科技有限公司 | 一种嵌合抗原受体、编码基因、表达载体及其应用 |
US10689456B2 (en) * | 2014-12-08 | 2020-06-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD70 chimeric antigen receptors |
-
2015
- 2015-04-09 US US15/531,626 patent/US10689456B2/en active Active
- 2015-04-09 PL PL15718065T patent/PL3230310T3/pl unknown
- 2015-04-09 ES ES19178931T patent/ES2921208T3/es active Active
- 2015-04-09 CN CN201580066498.4A patent/CN107207616B/zh active Active
- 2015-04-09 CA CA2970280A patent/CA2970280A1/en active Pending
- 2015-04-09 ES ES15718065T patent/ES2745153T3/es active Active
- 2015-04-09 EP EP15718065.4A patent/EP3230310B1/en active Active
- 2015-04-09 JP JP2017530742A patent/JP6724009B2/ja active Active
- 2015-04-09 DK DK19178931.2T patent/DK3597663T3/da active
- 2015-04-09 CN CN202111253336.5A patent/CN113968913A/zh active Pending
- 2015-04-09 PT PT15718065T patent/PT3230310T/pt unknown
- 2015-04-09 EP EP19178931.2A patent/EP3597663B1/en active Active
- 2015-04-09 AU AU2015361261A patent/AU2015361261B2/en active Active
- 2015-04-09 WO PCT/US2015/025047 patent/WO2016093878A1/en active Application Filing
- 2015-04-09 SI SI201530869T patent/SI3230310T1/sl unknown
- 2015-04-09 EP EP22164990.8A patent/EP4043487A1/en active Pending
-
2020
- 2020-06-10 AU AU2020203836A patent/AU2020203836B2/en active Active
- 2020-06-19 US US16/906,061 patent/US11999796B2/en active Active
- 2020-06-24 JP JP2020109158A patent/JP7128860B2/ja active Active
-
2021
- 2021-11-30 AU AU2021277627A patent/AU2021277627B2/en active Active
-
2022
- 2022-06-07 JP JP2022092594A patent/JP2022137020A/ja active Pending
-
2024
- 2024-05-14 US US18/663,557 patent/US20240294665A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4043487A1 (en) | 2022-08-17 |
CN107207616B (zh) | 2021-11-19 |
US10689456B2 (en) | 2020-06-23 |
US20240294665A1 (en) | 2024-09-05 |
CN107207616A (zh) | 2017-09-26 |
ES2745153T3 (es) | 2020-02-27 |
EP3230310A1 (en) | 2017-10-18 |
JP7128860B2 (ja) | 2022-08-31 |
JP2022137020A (ja) | 2022-09-21 |
EP3597663A1 (en) | 2020-01-22 |
SI3230310T1 (sl) | 2019-11-29 |
AU2015361261A1 (en) | 2017-06-15 |
AU2020203836B2 (en) | 2021-09-09 |
AU2021277627B2 (en) | 2023-08-24 |
CN113968913A (zh) | 2022-01-25 |
PT3230310T (pt) | 2019-09-26 |
CA2970280A1 (en) | 2016-06-16 |
PL3230310T3 (pl) | 2020-02-28 |
US11999796B2 (en) | 2024-06-04 |
AU2020203836A1 (en) | 2020-07-02 |
EP3230310B1 (en) | 2019-06-12 |
US20180208671A1 (en) | 2018-07-26 |
JP2018505139A (ja) | 2018-02-22 |
JP6724009B2 (ja) | 2020-07-15 |
ES2921208T3 (es) | 2022-08-19 |
JP2020171292A (ja) | 2020-10-22 |
US20200317807A1 (en) | 2020-10-08 |
WO2016093878A1 (en) | 2016-06-16 |
EP3597663B1 (en) | 2022-04-06 |
AU2021277627A1 (en) | 2021-12-23 |
AU2015361261B2 (en) | 2020-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3597663T3 (da) | Kimære antigenreceptorer af anti-cd70 | |
DK3628687T3 (da) | Kimære bcma-antigenreceptorer | |
DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
DK3194434T3 (da) | Kimære antigenreceptorer | |
DK3102576T3 (da) | Dihydropyrrolopyridininhibitorer af ror-gamma | |
CL2016002196A1 (es) | Receptor antigénico quimérico | |
BR112017001385A2 (pt) | anticorpos anti-pd-1 | |
DK3851537T5 (da) | Behandling af hyperbilirubinæmi | |
DK3180331T3 (da) | Polymorfer af selinexor | |
DK3126395T3 (da) | Multispecifikke antistoffer | |
DK3160956T3 (da) | Inhibitorer af lysin-specifik demethylase-1 | |
DK3164380T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
DK3300500T3 (da) | Triazolagonister af apj-receptoren | |
DK3117030T3 (da) | Diagnosticering af sepsis | |
DK3143037T3 (da) | Alpha4beta7-integrin-thioether-peptidantagonister | |
DK3132009T3 (da) | Fremgangsmåde | |
DK3220891T3 (da) | Sublingual formulering af riluzol | |
DK3212637T3 (da) | Dopamin-d3-receptorantagonistforbindelser | |
DK3218033T3 (da) | Forstøvning af væsker | |
DK3511000T3 (da) | Krystallinsk form x2 af grapiprant | |
MA40836A (fr) | Procédures de semi-synthèse | |
DK3204352T3 (da) | Hæmmere af lysin-gingipain | |
DK3104847T3 (da) | Hidtil ukendt anvendelse af sigma-1-receptoragonistforbindelser | |
DK3125942T3 (da) | Forstøvning af immunoglobulin | |
DK3201323T3 (da) | Modificering af bakteriofag |